Go Pro

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:FRLN

Freeline Therapeutics (FRLN) Stock Price, News & Analysis

Freeline Therapeutics logo

About Freeline Therapeutics Stock (NASDAQ:FRLN)

Key Stats

Today's Range
$6.48
$6.48
50-Day Range
$6.43
$6.49
52-Week Range
$2.11
$8.74
Volume
N/A
Average Volume
12,055 shs
Market Capitalization
$28.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Receive FRLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Freeline Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

FRLN Stock News Headlines

Freeline Therapeutics Shareholders Approve Acquisition by Syncona
2:59 PM Friday. I make this trade.
Tim Sykes says he books gains almost every weekend using one simple move. The trade is placed around 2:59 pm on Friday, right before the market closes for the week. He breaks down the exact routine step by step for anyone curious how it works.tc pixel
Freeline Shareholders Approve Acquisition by Syncona
Freeline Therapeutics Holdings plc (FRLN)
See More Headlines

FRLN Stock Analysis - Frequently Asked Questions

Freeline Therapeutics Holdings plc (NASDAQ:FRLN) released its earnings results on Tuesday, November, 9th. The company reported ($12.90) earnings per share for the quarter, topping analysts' consensus estimates of ($15.20) by $2.30.

Freeline Therapeutics's stock reverse split on the morning of Friday, May 12th 2023.The 1-15 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Freeline Therapeutics (FRLN) raised $150 million in an initial public offering (IPO) on Friday, August 7th 2020. The company issued 8,823,529 shares at $16.00-$18.00 per share. J.P. Morgan, Morgan Stanley and Evercore ISI served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Freeline Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Jabil (JBL), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
11/09/2021
Today
9/08/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:FRLN
CIK
1810031
Fax
N/A
Employees
152
Year Founded
2015

Profitability

EPS (Trailing Twelve Months)
($5.5939)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$88.97 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-150.46%
Return on Assets
-97.01%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.95
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$12.07 per share
Price / Book
0.54

Miscellaneous

Outstanding Shares
4,340,000
Free Float
4,259,000
Market Cap
$28.12 million
Optionable
Not Optionable
Beta
0.66

Social Links

10 Best Stocks to Own - Fall 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:FRLN) was last updated on 9/8/2026 by MarketBeat.com Staff.
From Our Partners